InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $2.250 0.07 (3.02%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,916 Mesoblast Stem Cells Regrow Knee Cartilage 12 Aug 2008 9:49AM $1.275 $2.245 risen by 76.08%
$2,916 Mesoblast`s Adult Stem Cells Repair Non Healing Bones 6 Aug 2008 8:30AM $1.200 $2.245 risen by 87.08%
$2,916 Appendix 4C - quarterly 31 Jul 2008 2:07PM $1.200 $2.245 risen by 87.08%
$2,916 Mesoblast Investor Briefing - The CEO Transcript 21 Jul 2008 12:14PM $1.200 $2.245 risen by 87.08%
$2,916 Key Stem Cell Patent Granted in United States 16 Jul 2008 10:15AM $1.055 $2.245 risen by 112.80%
$2,916 ALLOGENEIC STEM CELLS EFFECTIVELY TREAT EYE DISEASES 10 Jul 2008 10:26AM $0.980 $2.245 risen by 129.08%
$2,916 US FDA Clears Phase 2 Trial For Congestive Heart Failure 5 Jun 2008 10:40AM $0.920 $2.245 risen by 144.02%
$2,916 Appendix 4C - quarterly 29 Apr 2008 7:30PM $0.735 $2.245 risen by 205.44%
$2,916 Cells Show Sustained Effect for Knee Osteoarthritis 17 Apr 2008 11:41AM $0.630 $2.245 risen by 256.35%
$2,916 Spinal Fusion Clinical Program Update 9 Apr 2008 8:57AM $0.680 $2.245 risen by 230.15%
$2,916 U.S. Heart Attack Trial Update 7 Apr 2008 9:54AM $0.660 $2.245 risen by 240.15%
$2,916 Half Yearly Report and Accounts 27 Feb 2008 10:24AM $0.700 $2.245 risen by 220.71%
$2,916 Agreement with Abbott for Stem Cell Heart Failure Therapy 19 Feb 2008 10:01AM $0.835 $2.245 risen by 168.86%
$2,916 Bone Repair Trial Results Show Stem Cells Speed Up Healing 13 Feb 2008 9:06AM $0.830 $2.245 risen by 170.48%
$2,916 Appendix 4C - quarterly 31 Jan 2008 4:47PM $0.915 $2.245 risen by 145.36%
$2,916 Mesoblast Raises New Capital to Expand Clinical Programs 10 Dec 2007 10:11AM $1.300 $2.245 risen by 72.69%
$2,916 Trading Halt 6 Dec 2007 1:52PM n/a $2.245 n/a
$2,916 Appendix 4C - quarterly 31 Oct 2007 3:19PM $1.400 $2.245 risen by 60.36%
$2,916 Preliminary Final Report 31 Aug 2007 8:27AM $1.525 $2.245 risen by 47.21%
$2,916 Stem Cells Protect Knee Cartilage in Osteoarthritis 20 Aug 2007 9:25AM $1.740 $2.245 risen by 29.02%
$2,916 Successful Clinical Outcomes in Cell Heart Trial 10 Aug 2007 8:39AM $1.950 $2.245 risen by 15.13%
$2,916 Appendix 4C - quarterly 27 Jul 2007 5:45PM $2.020 $2.245 risen by 11.14%
$2,916 Mesoblast Begins Vertebral Disc Cartilage Program 24 Jul 2007 10:37AM $2.000 $2.245 risen by 12.25%
$2,916 Mesoblast Begins Trials Using Off The Shelf Stem Cells 16 Jul 2007 9:31AM $2.000 $2.245 risen by 12.25%
$2,916 Strong Interim Results in Fracture Repair Trial 18 Jun 2007 10:43AM $2.180 $2.245 risen by 2.98%

1101 - 1125 of 1172 results

Page 45 of 47

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.